Tibet Rhodiola Pharmaceutical Holding Co - Asset Resilience Ratio

Latest as of September 2025: 21.16%

Tibet Rhodiola Pharmaceutical Holding Co (600211) has an Asset Resilience Ratio of 21.16% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Tibet Rhodiola Pharmaceutical Holding Co carry for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥1.23 Billion

≈ $180.10 Million USD Cash + Short-term Investments

Total Assets

CN¥5.82 Billion

≈ $851.11 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2002–2024)

This chart shows how Tibet Rhodiola Pharmaceutical Holding Co's Asset Resilience Ratio has changed over time. See Tibet Rhodiola Pharmaceutical Holding Co book value and equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Tibet Rhodiola Pharmaceutical Holding Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Tibet Rhodiola Pharmaceutical Holding Co worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥1.23 Billion	21.16%
Total Liquid Assets	CN¥1.23 Billion	21.16%

Asset Resilience Insights

Good Liquidity Position: Tibet Rhodiola Pharmaceutical Holding Co maintains a healthy 21.16% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Tibet Rhodiola Pharmaceutical Holding Co Industry Peers by Asset Resilience Ratio

Compare Tibet Rhodiola Pharmaceutical Holding Co's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Zhejiang Huahai Pharmaceutical Co Ltd SHG:600521	Drug Manufacturers - Specialty & Generic	0.44%
Emcure Pharmaceuticals Ltd NSE:EMCURE	Drug Manufacturers - Specialty & Generic	1.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Ningbo Menovo Pharm Co Ltd SHG:603538	Drug Manufacturers - Specialty & Generic	2.69%
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Changzhou Qianhong Biopharma Co Ltd SHE:002550	Drug Manufacturers - Specialty & Generic	20.24%
Hunan Warrant Pharmaceutical Co. Ltd. A SHG:688799	Drug Manufacturers - Specialty & Generic	0.40%

Annual Asset Resilience Ratio for Tibet Rhodiola Pharmaceutical Holding Co (2002–2024)

The table below shows the annual Asset Resilience Ratio data for Tibet Rhodiola Pharmaceutical Holding Co.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	20.57%	CN¥976.62 Million ≈ $142.91 Million	CN¥4.75 Billion ≈ $694.68 Million	+9.34pp
2023-12-31	11.23%	CN¥515.34 Million ≈ $75.41 Million	CN¥4.59 Billion ≈ $671.27 Million	-8.10pp
2022-12-31	19.33%	CN¥792.49 Million ≈ $115.97 Million	CN¥4.10 Billion ≈ $599.87 Million	+5.19pp
2021-12-31	14.14%	CN¥537.87 Million ≈ $78.71 Million	CN¥3.80 Billion ≈ $556.45 Million	+13.64pp
2020-12-31	0.51%	CN¥14.96 Million ≈ $2.19 Million	CN¥2.94 Billion ≈ $430.84 Million	-2.74pp
2019-12-31	3.25%	CN¥90.00 Million ≈ $13.17 Million	CN¥2.77 Billion ≈ $404.93 Million	+0.41pp
2016-12-31	2.84%	CN¥65.00 Million ≈ $9.51 Million	CN¥2.29 Billion ≈ $335.20 Million	+2.80pp
2010-12-31	0.04%	CN¥308.80K ≈ $45.19K	CN¥735.47 Million ≈ $107.62 Million	-0.05pp
2009-12-31	0.10%	CN¥709.60K ≈ $103.84K	CN¥743.70 Million ≈ $108.83 Million	+0.08pp
2008-12-31	0.01%	CN¥112.40K ≈ $16.45K	CN¥829.66 Million ≈ $121.41 Million	-0.03pp
2007-12-31	0.04%	CN¥339.80K ≈ $49.72K	CN¥831.96 Million ≈ $121.74 Million	+0.01pp
2006-12-31	0.03%	CN¥252.00K ≈ $36.88K	CN¥866.90 Million ≈ $126.86 Million	+0.02pp
2005-12-31	0.01%	CN¥114.60K ≈ $16.77K	CN¥820.62 Million ≈ $120.08 Million	-0.46pp
2004-12-31	0.48%	CN¥3.69 Million ≈ $540.55K	CN¥777.25 Million ≈ $113.74 Million	-0.03pp
2003-12-31	0.51%	CN¥3.81 Million ≈ $557.96K	CN¥754.36 Million ≈ $110.39 Million	+0.05pp
2002-12-31	0.46%	CN¥3.37 Million ≈ $492.55K	CN¥733.08 Million ≈ $107.27 Million	--

pp = percentage points

About Tibet Rhodiola Pharmaceutical Holding Co

SHG:600211 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.96 Billion

CN¥13.38 Billion CNY

Market Cap Rank

#6402 Global

#1444 in China

Share Price

CN¥41.50

Change (1 day)

+2.57%

52-Week Range

CN¥35.59 - CN¥56.43

All Time High

CN¥165.99